Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder

Официальное название

The Impact of Health Literacy on the Attitudes Toward Pharmacological Treatment in Patients With Schizophrenia Spectrum Disorder

Обзор

The Impact of Health Literacy on the Attitudes toward Pharmacological Treatment in Patients with Schizophrenia Spectrum Disorder This interventional study is aimed at: * assessing and improving the health literacy and * assessing the attitude towards treatment of patients with schizophrenia spectrum disorders while they are admitted to the inpatient psychiatric unit.

Подробное описание

The study will take place at University Medical Center in New Orleans, LA and will include 34 patients with a schizophrenia spectrum disorder diagnosis who are admitted to the psychiatric unit. Participants will take tests to assess their knowledge of SSD before and after receiving educational materials during their hospitalization. They will also receive questionnaires assessing their attitudes toward treatment before and after the educational interventions. After each patient is provided with educational material, they will be allowed to ask the healthcare provider questions pertaining to schizophrenia. Following discharge, patients will be followed for a total of 12 months, where they will be called to answer questions about medication adherence.

Вмешательства

• Поведенческое Educational sessions
  Patients will be given an educational pamphlet with information about schizophrenia spectrum disorders, including prognosis and management options. Following this, they will be allowed to ask the doctor any questions they have pertaining to schizophrenia spectrum disorder. In the second educational session, patients will watch a video containing information about schizophrenia spectrum disorders. Following this, they will be allowed to ask the doctor any questions they have pertaining to this to

Первичные конечные точки

• Post-intervention KAST (Knowledge About Schizophrenia Test) scores [Срок оценки: This will be collected on Day 5 of the study, after the participant has completed both educational sessions.]
• Post-intervention ATT (Attitudes Toward Treatment) scores [Срок оценки: This will be collected on Day 5 of the study, after the participant has completed both educational sessions.]

Вторичные конечные точки (1)

• MARS (Medication Adherence Rating Scale) scores [Срок оценки: This questionnaire will be given on a monthly basis in the follow up period, for a total of 12 months.]

Критерии участия

Критерии включения

• Patients admitted to the University Medical Center-New Orleans (UMCNO) inpatient behavioral health unit ages 18 and older with a new or previous diagnosis of schizophrenia spectrum disorder outside of substance use disorders
• Patients must be proficient in English.
• Patients must have a government issued social security number (required for reimbursement through the university).

Критерии исключения

• Patients at UMCNO that are ages 17 or younger
• Patients with SSD and concomitant intellectual disability, as evidenced by prior documented history on chart review or patients suspected to have intellectual disability or impairment based on clinical interactions
• Patients with concomitant substance use and documentation of psychosis being resolved after a period of washout and without the use of psychotropic medications
• Patients unable to complete health literacy assessments, attitude towards treatment assessments, and IQ testing due to severity of symptoms during hospitalization
• Patients that are not proficient in English
• Patients that do not have a government issued social security number

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Другое

Центры проведения

США · 1 центр

• University Medical Center — New Orleans

Публикации

• Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: A measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288. doi: 10.1111/bcp.14193. Epub 2020 May 18. PMID 31823381
• Kampman O, Lehtinen K, Lassila V, Leinonen E, Poutanen O, Koivisto A. Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res. 2000 Oct 27;45(3):223-34. doi: 10.1016/s0920-9964(99)00204-2. PMID 11042440
• Chan KW, Hui LM, Wong HY, Lee HM, Chang WC, Chen YH. Medication adherence, knowledge about psychosis, and insight among patients with a schizophrenia-spectrum disorder. J Nerv Ment Dis. 2014 Jan;202(1):25-9. doi: 10.1097/NMD.0000000000000068. PMID 24375208
• von dem Knesebeck O, Mnich E, Daubmann A, Wegscheider K, Angermeyer MC, Lambert M, Karow A, Harter M, Kofahl C. Socioeconomic status and beliefs about depression, schizophrenia and eating disorders. Soc Psychiatry Psychiatr Epidemiol. 2013 May;48(5):775-82. doi: 10.1007/s00127-012-0599-1. Epub 2012 Oct 10. PMID 23052428
• Tsai KY, Chung TC, Lee CC, Chou YM, Su CY, Shen SP, Lin CH, Chou FH. Is low individual socioeconomic status (SES) in high-SES areas the same as low individual SES in low-SES areas: a 10-year follow-up schizophrenia study. Soc Psychiatry Psychiatr Epidemiol. 2014 Jan;49(1):89-96. doi: 10.1007/s00127-013-0716-9. Epub 2013 Jun 2. PMID 23728232
• Sharp HC. Vasectomy as a means of preventing procreation in defectives. J Am Med Assoc. 1909 Dec 4;53(23):1897-902. doi: 10.1001/jama.1909.92550230009002e. PMID 12334406
• Freimuth VS, Quinn SC, Thomas SB, Cole G, Zook E, Duncan T. African Americans' views on research and the Tuskegee Syphilis Study. Soc Sci Med. 2001 Mar;52(5):797-808. doi: 10.1016/s0277-9536(00)00178-7. PMID 11218181
• Hamilton LA, Aliyu MH, Lyons PD, May R, Swanson CL Jr, Savage R, Go RC. African-American community attitudes and perceptions toward schizophrenia and medical research: an exploratory study. J Natl Med Assoc. 2006 Jan;98(1):18-27. PMID 16532974

Идентификаторы

NCT: NCT07488156 · 8277 · R076477SCH4075

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗